Demographic, clinical, and treatment data for the patient cohort
| . | Entire cohort (N = 124) . | RTX (N = 60) . | No RTX (N = 64) . |
|---|---|---|---|
| Study site, n (%) | |||
| Harvard Consortium | 91 (73) | 46 (77) | 45 (70) |
| University of Washington | 17 (14) | 9 (15) | 8 (13) |
| Boston Medical Center | 16 (13) | 5 (8) | 11 (17) |
| Type of presentation, n (%) | |||
| First-time | 104 (84) | 50 (83) | 54 (84) |
| Presenting in relapse | 20 (16) | 10 (17) | 10 (16) |
| Sex, n (%) | |||
| Male | 38 (31) | 18 (30) | 20 (31) |
| Female | 86 (69) | 42 (70) | 44 (69) |
| Age, median (IQR), y | 42 (31-52) | 41 (31-52) | 43 (31-53) |
| ABO blood group, n (%) | |||
| Group O | 64 (52) | 31 (52) | 33 (52) |
| Non-group O | 58 (47) | 27 (45) | 31 (48) |
| Unknown | 2 (1) | 2 (3) | 0 (0) |
| Ethnicity, n (%) | |||
| White | 67 (54) | 34 (57) | 33 (52) |
| Nonwhite | 52 (42) | 24 (40) | 28 (44) |
| Unknown | 5 (4) | 2 (3) | 3 (5) |
| Laboratory values, median (IQR) | |||
| ADAMTS13 activity, %* | 0 (0-0) | 0 (0-0) | 0 (0-0) |
| ADAMTS13 inhibitor, BU | 1.4 (0.7-2.0) | 1.4 (0.8-2.0) | 1.4 (0.6-2.0) |
| Hemoglobin, g/dL | 8.9 (7.3-10.1) | 8.6 (7.1-9.6) | 9.4 (7.4-10.8) |
| Platelets, ×109/L | 16 (10-22) | 15 (10-20) | 17 (11-24) |
| Lactate dehydrogenase, U/L | 1090 (742-1402) | 1089 (734-1504) | 1090 (782-1329) |
| Cr, mg/dL | 1.0 (0.8-1.4) | 1.0 (0.7-1.3) | 1.1 (0.9-1.6) |
| Total bilirubin, mg/dL | 2.3 (1.5-3.1) | 2.4 (1.5-3.1) | 2.3 (1.5-3.1) |
| Reticulocyte, % | 4.6 (2.9-8.3) | 6.2 (3.7-9.9) | 3.6 (2.6-6.4) |
| Day 4 platelets, ×109/L | 131 (68-181) | 111 (49-160) | 159 (107-216) |
| Days to platelet normalization | 5 (4-8) | 6 (4-15.3) | 4 (3.5-6) |
| Treatment | |||
| No. (%) treated with TPE | 120 (97) | 60 (100) | 60 (94) |
| Median (IQR) TPE procedures | 15 (8-23) | 22 (14-29) | 9 (6-15) |
| No. (%) treated with steroids | 113 (91) | 58 (97) | 56 (88) |
| No. (%) treated with second-line drug† | 8 (6.5) | 8 (13) | 0 (0) |
| Median (IQR) hospital stay, d | 12 (8-20) | 18 (11-27) | 9 (7-14) |
| . | Entire cohort (N = 124) . | RTX (N = 60) . | No RTX (N = 64) . |
|---|---|---|---|
| Study site, n (%) | |||
| Harvard Consortium | 91 (73) | 46 (77) | 45 (70) |
| University of Washington | 17 (14) | 9 (15) | 8 (13) |
| Boston Medical Center | 16 (13) | 5 (8) | 11 (17) |
| Type of presentation, n (%) | |||
| First-time | 104 (84) | 50 (83) | 54 (84) |
| Presenting in relapse | 20 (16) | 10 (17) | 10 (16) |
| Sex, n (%) | |||
| Male | 38 (31) | 18 (30) | 20 (31) |
| Female | 86 (69) | 42 (70) | 44 (69) |
| Age, median (IQR), y | 42 (31-52) | 41 (31-52) | 43 (31-53) |
| ABO blood group, n (%) | |||
| Group O | 64 (52) | 31 (52) | 33 (52) |
| Non-group O | 58 (47) | 27 (45) | 31 (48) |
| Unknown | 2 (1) | 2 (3) | 0 (0) |
| Ethnicity, n (%) | |||
| White | 67 (54) | 34 (57) | 33 (52) |
| Nonwhite | 52 (42) | 24 (40) | 28 (44) |
| Unknown | 5 (4) | 2 (3) | 3 (5) |
| Laboratory values, median (IQR) | |||
| ADAMTS13 activity, %* | 0 (0-0) | 0 (0-0) | 0 (0-0) |
| ADAMTS13 inhibitor, BU | 1.4 (0.7-2.0) | 1.4 (0.8-2.0) | 1.4 (0.6-2.0) |
| Hemoglobin, g/dL | 8.9 (7.3-10.1) | 8.6 (7.1-9.6) | 9.4 (7.4-10.8) |
| Platelets, ×109/L | 16 (10-22) | 15 (10-20) | 17 (11-24) |
| Lactate dehydrogenase, U/L | 1090 (742-1402) | 1089 (734-1504) | 1090 (782-1329) |
| Cr, mg/dL | 1.0 (0.8-1.4) | 1.0 (0.7-1.3) | 1.1 (0.9-1.6) |
| Total bilirubin, mg/dL | 2.3 (1.5-3.1) | 2.4 (1.5-3.1) | 2.3 (1.5-3.1) |
| Reticulocyte, % | 4.6 (2.9-8.3) | 6.2 (3.7-9.9) | 3.6 (2.6-6.4) |
| Day 4 platelets, ×109/L | 131 (68-181) | 111 (49-160) | 159 (107-216) |
| Days to platelet normalization | 5 (4-8) | 6 (4-15.3) | 4 (3.5-6) |
| Treatment | |||
| No. (%) treated with TPE | 120 (97) | 60 (100) | 60 (94) |
| Median (IQR) TPE procedures | 15 (8-23) | 22 (14-29) | 9 (6-15) |
| No. (%) treated with steroids | 113 (91) | 58 (97) | 56 (88) |
| No. (%) treated with second-line drug† | 8 (6.5) | 8 (13) | 0 (0) |
| Median (IQR) hospital stay, d | 12 (8-20) | 18 (11-27) | 9 (7-14) |